Novo Nordisk stock is back under the microscope after a weak three year share price run, even as its valuation checks screen it as attractively priced on several fronts. Recent setbacks in parts of the drug pipeline have weighed on sentiment, while strong demand for obesity treatments keeps investors focused on what the current price actually implies.
- The share price has fallen 46.9% over the past three years, which means anyone buying today is doing so after a sizeable reset in market expectations.
- Strong uptake of GLP-1 products such as Wegovy can support optimism on long term earnings power. At the same time, recent trial failures for drugs like ziltivekimab highlight the risk that diversification efforts may not always translate into future cash flows.
- Novo Nordisk scores well on valuation. The broader checks point to a stock that looks relatively cheap on 5 of 6 measures compared with its fundamentals and peers.
The issue now is whether Novo Nordisk's current price properly reflects both the strength of its obesity franchise and the execution risks in its broader pipeline and capital allocation plans.
Find out why Novo Nordisk's -1.2% return over the last year is lagging behind its peers.
Does Novo Nordisk Look Undervalued on Earnings?
P/E is usually a good starting point for Novo Nordisk because earnings remain the key anchor for how the market prices large pharmaceutical stocks. Right now the stock trades on a P/E of 11.6x, which is well below both the global pharmaceuticals industry average of 21.2x and the peer group average of 24.2x.
The fair P/E ratio suggested by the model is 23.9x, which reflects what investors might typically pay given Novo Nordisk's margins, scale and risk profile. That is more than double the current 11.6x level, so the shares screen as materially undervalued on this framework. Despite the recent ziltivekimab trial failure and wider concerns about the pipeline beyond obesity and diabetes, the current P/E still sits at a sizeable discount to what the earnings profile would usually justify.
Overall, Novo Nordisk stock appears undervalued on its P/E multiple compared with both industry norms and the model's fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Novo Nordisk Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Novo Nordisk pick up where this valuation puzzle leaves off. They spell out the specific paths for Novo Nordisk's growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Where a single ratio or model gives one number, these narratives lay out the future that number assumes so you can track whether it continues to line up with reality.
Community views on Novo Nordisk sit on very different paths for how far the GLP-1 opportunity can actually translate into durable earnings.
Bull case: roughly fairly valued
"Despite current headwinds, penetration of GLP-1 therapies in both diabetes (only 7% of prescriptions) and obesity (less than 1% of those affected globally treated with branded medications) remains extremely low, suggesting a vast untapped patient pool that could drive significant long-term revenue growth as access and adoption increase..."
Read the full Bull Case to see why Novo Nordisk could be undervalued
Bear case: 6% overvalued
"Manufacturing capacity is constrained until roughly 2029, limiting volume growth regardless of demand..."
Read the full Bear Case to see why Novo Nordisk could be overvalued
Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!
The Bottom Line
Novo Nordisk screens as undervalued on earnings based on its current P/E discount to both peers and the modelled fair ratio. The key question is whether that discount reflects temporary caution around pipeline setbacks or a more permanent concern about concentration in obesity and diabetes. For you as an investor, the crux is whether Novo Nordisk can keep converting GLP-1 demand into durable earnings while proving that its broader pipeline and capital allocation can justify a higher multiple. That tension between franchise strength and execution risk is what will decide whether the current valuation represents a genuine opportunity or a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com